Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.

ABSTRACT:

Background

Attempts to identify opioid users at increased risk of escalating to opioid use disorder have had limited success. Data from a variety of sources suggest that genetic variation may mediate the subjective response to opioid drugs, and therefore contribute to their abuse potential. The goal of the current study was to observe the relationship between select genetic polymorphisms and the subjective effects of oxycodone under controlled clinical laboratory conditions.

Methods

Non-dependent, volunteers with some history of prescription opioid exposure (N = 36) provided a blood sample for analyses of variations in the genes that encode for the μ-, κ- and δ-opioid receptors, and the dopamine metabolizing enzyme, catechol-O-methyltransferase (COMT). Participants then comp

SUBMITTER: Jones JD 

PROVIDER: S-EPMC6801039 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature